Incyte (INCY) Invested Capital (2012 - 2026)
Incyte's (INCY) quarterly Invested Capital came in at $38.8 million in Q2 2026, down 17.14% YoY from $46.8 million in Q2 2025, and down 1.45% on a QoQ basis from $39.4 million in Q1 2026.
Analysis
Incyte (INCY) Invested Capital (2012 - 2026) Analysis & Trends
Incyte (INCY) has 14 years of Invested Capital data on file, last reported at $38.8 million in Q2 2026.
- Quarterly Invested Capital fell 17.14% year-over-year to $38.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $158.5 million (down 4.99% YoY) and the FY2025 annual result came in at $34.7 million, down 8.55% from the prior year.
- Invested Capital fell to $38.8 million in Q2 2026, from $39.4 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $46.8 million in Q2 2025 to a low of $32.6 million in Q4 2023.
- A 5-year average of $38.1 million and a median of $37.3 million in 2023 frame the typical range for Invested Capital.
- Annual changes were most pronounced in 2025 — Invested Capital advanced 26.07% — and 2026, when it fell 17.14%.
- Tracing INCY's Invested Capital over 5 years: stood at $33.3 million in 2022, then dropped by 1.99% to $32.6 million in 2023, then climbed by 16.44% to $38.0 million in 2024, then dropped by 8.55% to $34.7 million in 2025, then gained by 11.8% to $38.8 million in 2026.
- The last three Invested Capital figures came in at $38.8 million (Q2 2026), $39.4 million (Q1 2026), and $34.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 33.70 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 7.35 Bn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 6.25 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 19.13 Bn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 1.30 Bn |
| 10 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | 6.38 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.38 Bn |
| Mar 31, 2026 | 5.66 Bn |
| Dec 31, 2025 | 5.21 Bn |
| Sep 30, 2025 | 4.70 Bn |
| Jun 30, 2025 | 4.22 Bn |
| Mar 31, 2025 | 3.71 Bn |
| Dec 31, 2024 | 3.49 Bn |
| Sep 30, 2024 | 3.21 Bn |
| Jun 30, 2024 | 3.03 Bn |
| Mar 31, 2024 | 5.43 Bn |
| Dec 31, 2023 | 5.23 Bn |
| Sep 30, 2023 | 4.97 Bn |
| Jun 30, 2023 | 4.78 Bn |
| Mar 31, 2023 | 4.50 Bn |
| Dec 31, 2022 | 4.41 Bn |
| Sep 30, 2022 | 4.26 Bn |
| Jun 30, 2022 | 4.12 Bn |
| Mar 31, 2022 | 3.90 Bn |
| Dec 31, 2021 | 3.81 Bn |
| Sep 30, 2021 | 3.19 Bn |